Stock listing
Arvinas, Inc.
Selected listing: ARVN · NASDAQ · USD · US
Arvinas, Inc. (NASDAQ:ARVN), Health Technology. Latest release Oct 1, 2026: Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial…
- Ticker
- NASDAQ:ARVN
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Arvinas, Inc.
Arvinas, Inc. is a public company traded under the ticker ARVN in the American market. Arvinas focuses on developing innovative therapies for various diseases using its proprietary protein degradation technology.
Latest news from Arvinas, Inc.
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
October 1, 2026
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
September 30, 2026
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate
September 29, 2026
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 28, 2026
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
September 28, 2026